Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05796453 · ClinicalTrials.gov registry record · NA

Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix

A NA study of Presbyopia and Astigmatism, sponsored by Alcon Research.

Active
Registry status
NA
Development phase
470
Enrollment target
7
Study locations

NCT05796453: Active NA study of Presbyopia and Astigmatism, sponsored by Alcon Research.

NCT05796453 is a NA study of Presbyopia and Astigmatism that is active but no longer recruiting, run by Alcon Research. The registered enrollment target is 470 participants, above the 258-participant average among 38 other Presbyopia trials with a reported enrollment target (82% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05796453, a NA study of Presbyopia and Astigmatism, is active but no longer recruiting, sponsored by Alcon Research.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
470 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix Toric IOLs.

Primary Outcome

BCDVA will be assessed at a distance of 4 meters using letter charts and recorded in logarithm Minimum Angle of Resolution (logMAR).

Interventions

  • DEVICE Clareon Vivity IOL - Non Toric
  • DEVICE Clareon Vivity IOL - Toric
  • DEVICE Clareon PanOptix Trifocal IOL - Non Toric
  • DEVICE Clareon PanOptix Trifocal IOL - Toric

Study Locations (7)

California

  • Wolstan & Goldberg Eye Associates - Torrance

Florida

  • Levenson Eye Associates - Jacksonville

New York

  • Eye Surgeons of CNY - Liverpool

Oklahoma

  • Tulsa Ophthalmology - Tulsa

Texas

  • Chu Eye Institute - Fort Worth

Utah

  • The Eye Institute of Utah - Salt Lake City

Other

  • Centro Oftalmologico Metropolitano - San Juan

Trial Details

FieldValue
Enrollment Target 470 participants
Start Date 2023-09-19
Est. Completion 2028-06
Phase NA
Alcon Research

275 total trials

What the registry record for NCT05796453 still lists

NCT05796453 is an interventional study that assigns participants to a tested intervention. The registered 470 participants enrollment target is mid-sized for trials with a published cap, above the 258-participant average among 38 other Presbyopia trials with a reported enrollment target (82% higher).

The record links to 3 conditions, with Presbyopia appearing as the primary indexed condition, and to 4 interventions - of which Clareon Vivity IOL - Non Toric is the first listed.

NCT05796453 lists 7 locations in 7 states (California, Florida, New York).

Frequently Asked Questions

What is clinical trial NCT05796453 about?

NCT05796453 is a clinical study titled "Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix". The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix Toric IOLs.

What is the current status of trial NCT05796453?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 470 participants. The study started on 2023-09-19. Estimated completion is 2028-06.

What conditions does trial NCT05796453 study?

This clinical trial studies the following conditions: Presbyopia, Astigmatism, Aphakia.

What interventions are being tested in trial NCT05796453?

The interventions under investigation include: Clareon Vivity IOL - Non Toric (DEVICE), Clareon Vivity IOL - Toric (DEVICE), Clareon PanOptix Trifocal IOL - Non Toric (DEVICE), Clareon PanOptix Trifocal IOL - Toric (DEVICE).

Who is sponsoring clinical trial NCT05796453?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05796453 being conducted?

This trial has 7 study locations across California, Florida, New York, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Presbyopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05796453's enrollment target sits among peer trials

470 3rd of 38 higher than 36 of 38 other Presbyopia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Presbyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05256940 · 470 participants · NA

    Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide

  • NCT05458219 · 470 participants · Phase 1

    A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

  • NCT05850689 · 470 participants · Phase 3

    Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  • NCT05935384 · 470 participants

    SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05796453, the US trial registry maintained by the National Library of Medicine. NCT05796453 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.